AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 11 - (NewsRx.com & NewsRx.net) -- Researchers have evaluated melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
"Immunotherapy of melanoma is aimed to mobilize cytolytic CD8+ T cells playing a central role in protective immunity. Despite numerous clinical vaccine trials, only few patients exhibited strong antigen-specific T-cell activation, stressing the need to improve vaccine strategies. For a rational development, we propose to focus on molecularly defined vaccine components, and evaluate their immunogenicity with highly reproducible and standardized methods for ex vivo immune monitoring," scientists in Switzerland report.
"Careful immunogenicity comparison of vaccine formulations in phase I/II studies allow to select optimized vaccines for subsequent clinical efficacy testing in large scale phase III trials," wrote Daniel E. Speiser and colleagues at the Centre Hospitalier Universitaire Vaudois (CHUV).
Speiser and his coauthors published ...